Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.
about
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growthOsteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerCombined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic miceThe Promise of Preventive Cancer VaccinesEvolution of animal models in cancer vaccine developmentCancer immunopreventionChemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions.Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesionsCharacterizing complex polysera produced by antigen-specific immunization through the use of affinity-selected mimotopesTumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.Cytokines and cancer immunotherapy.An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survivalA mathematical-biological joint effort to investigate the tumor-initiating ability of Cancer Stem Cells.Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult miceIL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside.Multi-level model for the investigation of oncoantigen-driven vaccination effect.DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in miceSynthetic peptides as cancer vaccines.Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasisOncoantigens for an immune prevention of cancer.Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Antitumor immunization of mothers delays tumor development in cancer-prone offspring.Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumorsCancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains.The pH low insertion peptide pHLIP Variant 3 as a novel marker of acidic malignant lesionsPeptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyTriggering CD40 on endothelial cells contributes to tumor growthLeukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinomaInflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice.DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice.An evolutionary perspective on anti-tumor immunityLocal delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice
P2860
Q24548511-1CE86EC2-938A-417E-8D23-065C4847C01EQ24605866-E0FE6980-BD03-4627-88FD-47DE166AC87FQ24670549-1993D8A4-BDC1-44AF-A9F0-6AFB9912249FQ26783742-B9FD422D-E7B3-45E4-8A96-4C8089F6929EQ28080739-F8D48D60-2E80-466D-8F0F-F13CB53AAC1BQ28303393-2A25602B-370B-49DB-BFC1-76B98F5A0C22Q30493889-63A33E91-6D14-49DF-8A01-C319065AC915Q30862052-5E17C7B8-EC9E-42F5-A9D0-F6E8F9E68300Q30909247-56882046-C2FC-489A-98A0-5D96E834B3C7Q33434406-3D095BB8-2DC3-438D-9977-CC0F9A4053F0Q33763653-EECDAAC1-2CF2-430D-96EA-504A458C50CDQ33943142-67D308E4-91F2-40AB-9412-76490D62BD87Q34100841-47788AD5-E485-4B66-8AA5-050BCACEE3C4Q34128350-12D8FFB4-0D4E-457A-85B8-05336F102E62Q34288183-202BACFA-BFA9-4D6D-93E1-6EC777C0420EQ34521619-877CB8A5-DBA7-4D1A-9742-C23A01A2E026Q34598522-8988374E-922B-440F-80BB-A339039C77FAQ34701390-84A1717A-9F16-4D42-A2BE-4712604ABD4DQ34756500-30E386CC-4F5C-483F-9176-74163276B484Q34939255-95D8815D-5F03-416D-B594-F199BFFC534EQ34972916-8762B30F-AC7C-4039-BE6A-E07964B4F897Q35036388-B99E1526-B62B-485B-853E-DB16EB693414Q35083847-43125B40-E0E3-423F-9C70-E74F28F8E6DDQ35157433-14FC1D5A-CC9C-4FB6-B6E6-F38461001F5CQ35232253-5FA552A0-A7F0-4EA8-A863-74A97008FCF9Q35234774-3B826B52-473A-46A3-9064-3307662DDDF0Q35574950-149ED714-1573-44AF-BEFB-74DA0FF54A4BQ35799346-728D5CFB-A6DD-4504-A230-EE38D496DC85Q35890518-001F12D0-FC27-44C6-AD11-EF70C22425EFQ35918770-15F691D3-0232-47F3-BA53-794A3834C7ACQ35939476-A46A5073-48BA-4C00-9D64-1762BCB31A20Q35946329-739F0E25-6849-49F7-B306-79D4BA11314AQ36007167-793FFB0D-CC6C-4C9B-89CE-361576CCE683Q36116250-B36A2F4B-3451-4F8E-B1AA-0CFE87A1AB4FQ36228064-7E5A587D-685D-4118-A64F-3FEB79DFE3BDQ36371486-DC51AAF7-629A-4A8B-BA0E-84579C23E7EEQ36393263-306B3F34-AE92-4308-878D-EEB2D407A724Q36411564-18EB84E8-628F-4726-99E6-F0D6A7494092Q36522859-2C751721-3877-4C64-8105-5467785A18E2Q36580203-C07BCA10-773E-4545-A478-4555B3681E7D
P2860
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Interleukin 12-mediated preven ...... of Her-2/neu transgenic mice.
@ast
Interleukin 12-mediated preven ...... of Her-2/neu transgenic mice.
@en
type
label
Interleukin 12-mediated preven ...... of Her-2/neu transgenic mice.
@ast
Interleukin 12-mediated preven ...... of Her-2/neu transgenic mice.
@en
prefLabel
Interleukin 12-mediated preven ...... of Her-2/neu transgenic mice.
@ast
Interleukin 12-mediated preven ...... of Her-2/neu transgenic mice.
@en
P2093
P2860
P50
P356
P1476
Interleukin 12-mediated preven ...... s of Her-2/neu transgenic mice
@en
P2093
C De Giovanni
E Di Carlo
G Nicoletti
L Landuzzi
P Bouchard
P2860
P304
P356
10.1084/JEM.188.3.589
P407
P50
P577
1998-08-01T00:00:00Z